Abivax announced positive phase 2b clinical induction and results for ABX464 in the treatment of patients with moderate to severe ulcerative colitis, according to a press release.

In a randomized, double-blind, placebo-controlled trial, patients treated with once-daily ABX464 in each dosage group (25 mg, 50 mg and 100 mg) met the primary study endpoint of statistically significant reduction of Modified Mayo Score at 8-weeks. Further, compared with placebo, patients dosed with ABX464 demonstrated endoscopic improvement, clinical remission, clinical response and reduction of fecal calprotectin.

Full Article: https://www.healio.com/news/gastroenterology/20210607/abx464-safe-effective-in-treating-patients-with-ulcerative-colitis